

Vol 1, No 3 (2009)

Mol Cell Pharmacol

Table of Contents

PharmSights

PUMA Kills Stem Cells to Stall Cancer? <i>Jian Yu</i>	ABSTRACT PDF 112-118
Transgenic Humanized AHR Mouse Reveals Differences between Human and Mouse AHR Ligand Selectivity <i>Colin A. Flaveny, Gary H. Perdew</i>	ABSTRACT PDF 119-123
Developing Antiepileptogenic Drugs for Acquired Epilepsy: Targeting the Mammalian Target of Rapamycin (mTOR) Pathway <i>Ling-Hui Zeng, Nicholas R. Rensing, Michael Wong</i>	ABSTRACT PDF 124-129

Research Articles

Nucleolin Binds to the Proliferating Cell Nuclear Antigen and Inhibits Nucleotide Excision Repair <i>Chonglin Yang, Myoung Sook Kim, Devulapalli Chakravarty, Fred E. Indig, France Carrier</i>	ABSTRACT PDF 130-137
Extraction, Characterization, Stability and Biological Activity of Flavonoids Isolated from Chamomile Flowers <i>Janmejai K. Srivastava, Sanjay Gupta</i>	ABSTRACT PDF 138-147

Reviews

RanGTPase: A Key Regulator of Nucleocytoplasmic Trafficking <i>Ki Lui, Ying Huang</i>	ABSTRACT PDF 148-156
The Regulation of YY1 in Tumorigenesis and its Targeting Potential in Cancer Therapy <i>Guangchao Sui</i>	ABSTRACT PDF 157-176

FDA Corner

FDA Approves New Drug Treatment for Type 2 Diabetes	ABSTRACT PDF 177
FDA Approves First Maintenance Drug Therapy for Advanced Lung Cancer	ABSTRACT PDF 177
FDA Approves Multaq to Treat Heart Rhythm Disorder	ABSTRACT PDF 178
FDA Approves Drug for Treatment of Aggressive Brain Cancer	ABSTRACT PDF 178-179